6 [12] Y. Onishi, Z. Fehervari, T. Yamaguchi, and S. Sakaguchi, “Foxp3 natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10113–10118, 2008. [13] G. Pratt, O. Goodyear, and P. Moss, “Immunodeﬁciency and immunotherapy in multiple myeloma,” British Journal of Haematology, vol. 138, no. 5, pp. 563–579, 2007. [14] M. J. Berendt and R. J. North, “T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor,” Journal of Experimental Medicine, vol. 151, no. 1, pp. 69–80, 1980. [15] G. Zhou and H. I. Levitsky, “Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-speciﬁc tolerance,” Journal of Immunology, vol. 178, no. 4, pp. 2155–2162, 2007. [16] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3+ programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. [17] S. F. Ziegler, “FOXP3: of mice and men,” Annual Review of Immunology, vol. 24, pp. 209–226, 2006. [18] K. Wing, Y. Onishi, P. Prieto-Martin et al., “CTLA-4 control over Foxp3 regulatory T cell function,” Science, vol. 322, no. 5899, pp. 271–275, 2008. [19] M. L. Chen, M. J. Pittet, L. Gorelik et al., “Regulatory T cells suppress tumor-speciﬁc CD8 T cell cytotoxicity through TGF-β signals in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 2, pp. 419–424, 2005. [20] F. Ghiringhelli, C. Me´nard, F. Martin, and L. Zitvogel, “The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression,” Immunological Reviews, vol. 214, no. 1, pp. 229–238, 2006. [21] H. W. Lim, P. Hillsamer, A. H. Banham, and C. H. Kim, “Cutting edge: direct suppression of B cells by CD4+CD25+ regulatory T cells,” Journal of Immunology, vol. 175, no. 7, pp. 4180–4183, 2005. [22] P. G. Coulie and T. Connerotte, “Human tumor-speciﬁc T lymphocytes: does function matter more than number?” Cur- rent Opinion in Immunology, vol. 17, no. 3, pp. 320–325, 2005. [23] M. Harris, “Monoclonal antibodies as therapeutic agents for cancer,” Lancet Oncology, vol. 5, no. 5, pp. 292–302, 2004. [24] D. H. Raulet, “Interplay of natural killer cells and their receptors with the adaptive immune response,” Nature Immunology, vol. 5, no. 10, pp. 996–1002, 2004. [25] S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama, “Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody,” Cancer Research, vol. 59, no. 13, pp. 3128–3133, 1999. [26] J. Shimizu, S. Yamazaki, and S. Sakaguchi, “Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity,” Journal of Immunology, vol. 163, no. 10, pp. 5211–5218, 1999. [27] C. L. Bennett, J. Christie, F. Ramsdell et al., “The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,” Nature Genetics, vol. 27, no. 1, pp. 20–21, 2001. [28] M. E. Brunkow, E. W. Jeﬀery, K. A. Hjerrild et al., “Disruption of a new forkhead/winged-helix protein, scurﬁn, results in the fatal lymphoproliferative disorder of the scurfy mouse,” Nature Genetics, vol. 27, no. 1, pp. 68–73, 2001. Bone Marrow Research [29] R. S. Wildin, F. Ramsdell, J. Peake et al., “X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy,” Nature Genetics, vol. 27, no. 1, pp. 18–20, 2001. [30] L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. [31] R. P. Petersen, M. J. Campa, J. Sperlazza et al., “Tumor inﬁltrating FOXP3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients,” Cancer, vol. 107, no. 12, pp. 2866–2872, 2006. [32] M. Beyer, M. Kochanek, T. Giese et al., “In vivo peripheral expansion of naive CD4+CD25+ FoxP3+ regulatory T cells in patients with multiple myeloma,” Blood, vol. 107, no. 10, pp. 3940–3949, 2006. [33] S. Feyler, M. Von Lilienfeld-Toal, S. Jarmin et al., “CD4+CD25+FoxP3v regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden,” British Journal of Haematology, vol. 144, no. 5, pp. 686–695, 2009. [34] L. S. Taams, J. Smith, M. H. Rustin, M. Salmon, L. W. Poulter, and A. N. Akbar, “Human anergic/suppressive CD4+CD25+ T cells: a highly diﬀerentiated and apoptosis-prone population,” European Journal of Immunology, vol. 31, no. 4, pp. 1122–1131, 2001. [35] H. Jonuleit, E. Schmitt, M. Stassen, A. Tuettenberg, J. Knop, and A. H. Enk, “Identiﬁcation and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood,” Journal of Experimental Medicine, vol. 193, no. 11, pp. 1285–1294, 2001. [36] R. H. Prabhala, P. Neri, J. E. Bae et al., “Dysfunctional T regulatory cells in multiple myeloma,” Blood, vol. 107, no. 1, pp. 301–304, 2006. [37] J. Radl, J. W. Croese, C. Zurcher, M. H. M. Van Den Enden- Vieveen, and A. M. De Leeuw, “Animal model of human disease. Multiple myeloma,” American Journal of Pathology, vol. 132, no. 3, pp. 593–597, 1988. [38] K. Vanderkerken, H. De Raeve, E. Goes et al., “Organ involvement and phenotypic adhesion proﬁle of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse,” British Journal of Cancer, vol. 76, no. 4, pp. 451–460, 1997. [39] P. Correale, M. G. Cusi, K. Y. Tsang et al., “Chemo-immuno- therapy of metastatic colorectal carcinoma with gemci-tabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in meta- static colon cancer patients,” Journal of Clinical Oncology, vol. 23, no. 35, pp. 8950–8958, 2005. [40] J. M. D. Plate, A. E. Plate, S. Shott, S. Bograd, and J. E. Harris, “Eﬀect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas,” Cancer Immunology, Immunotherapy, vol. 54, no. 9, pp. 915–925, 2005. [41] S. Barni, P. Lissoni, F. Paolorossi et al., “Mitoxantrone as a single agent in pretreated metastatic breast cancer: eﬀects on T lymphocyte subsets and their relation to clinical response,” Tumori, vol. 77, no. 3, pp. 227–231, 1991. [42] U. Hegde, A. Chhabra, S. Chattopadhyay, R. Das, S. Ray, and N. G. Chakraborty, “Presence of low dose of ﬂudarabine in cultures blocks regulatory T cell expansion and maintains tumor-speciﬁc cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes,” Pathobiology, vol. 75, no. 3, pp. 200–208, 2008.